SOURCE: Atossa Genetics Inc.
SEATTLE, WA--(Marketwired - Jan 23, 2014) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it intends to offer units consisting of shares of common stock and warrants in a public offering. While the offering is expected to price before 9:30 am EST on January 24, 2014, the offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Dawson James Securities, Inc. will serve as the sole book-running manager for the offering.
A registration statement relating to the shares of common stock and warrants which are being offered in the offering, and the shares of common stock issuable upon exercise of the warrants which are being offered in the offering, has been filed with, and declared effective by, the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement, as well as a final prospectus supplement, relating to the offering will be filed with the SEC, each of which will form a part of the effective registration statement. When available, copies of the preliminary and final prospectus supplements relating to these securities may be obtained by visiting the SEC's website at www.sec.gov or from Dawson James Securities, Inc., 1 North Federal Highway, Boca Raton, FL, 33432, or via telephone at (866) 928-0928.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Atossa Genetics
Atossa Genetics Inc. is focused on proprietary products and services related to breast health through the commercialization of medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc., the offering of laboratory services and tests. For additional information, please visit www.atossagenetics.com.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including our ability to sell the securities in the offering described in this news release, the risks and uncertainties associated with actions by the FDA, including timing of review by the FDA of 510(k) submissions, and actions related thereto, the outcome or timing of regulatory clearances needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the efficacy of Atossa's products and services, performance of distributors, estimated future expenses and cash needs, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.